The Clozapine Test

Who is this test for?

All people for whom clozapine is being considered plus:

• Current clozapine patients whose BEN status is unknown.
• Current clozapine patients who cannot achieve a therapeutic level despite high dose clozapine.
• Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic

In addition, patients already receiving clozapine:

• Patients with only a partial treatment response
• Patients where neutrophil counts necessitate interruption of treatment
• Patients with possible benign ethnic neutropenia but their status is uncertain

Although the benefits of clozapine are widely recognised, every individual decision to prescribe clozapine involves a number of questions:

• How likely is my patient to respond?
• The average risk of agranulocytosis is about 1 in 250. Some patients have higher risk than others. How do I know the level of my patient’s risk?
• Apart from trial and error, how do I know what dose to aim for in my patient?

With The Clozapine Test, before making the decision to prescribe, clinicians can be more certain about:

• The likelihood that an individual patient will respond to treatment
• Whether an individual is at high or low risk for agranulocytosis and whether or not they have Benign Ethnic Neutropenia
• The starting dose and the optimal target dose

How does the test work?

• Treatment response: three independent genetic variants are analysed and inserted into a mathematical model to predict how likely a person is to respond to clozapine. 
• Agranulocytosis risk: a number of genetic variants that are linked to high risk for neutropenia and agranulocytosis are examined. We test for a single genetic variant to determine benign ethnic neutropenia status.
• Target dose: the function of four metabolising enzymes is evaluated to predict a target dose for clozapine.